Making top-quality cancer care accessible to all.100% free, no account required.

Looking at Vitamin C and Chemotherapy for Treating Lymphoma and Related Conditions

NCT03418038 · Recruiting
About this trial

This trial looks at the use of ascorbic acid, also known as vitamin C, along with chemotherapy to help treat certain types of lymphoma that have returned or didn't respond to previous treatments. Researchers believe that ascorbic acid may help make cancer cells more sensitive to chemotherapy. The main goal is to see how well this combination works for patients with different types of lymphoma and other related blood disorders.

Locations and contact

This trial is running at 4 locations in the United States. 1 of them are currently recruiting.

United States4 locations · 1 recruiting
  • Mayo Clinic in RochesterRochester, MinnesotaRecruiting
  • Mayo Clinic Health System-Eau Claire ClinicEau Claire, WisconsinNot Yet Recruiting
  • Mayo Clinic Health Systems-MankatoMankato, MinnesotaNot Yet Recruiting
  • Mayo Clinic Health System-Franciscan HealthcareLa Crosse, WisconsinActive Not Recruiting
Who to ask about joining
Clinical Trials Referral Office855-776-0015mayocliniccancerstudies@mayo.edu
Who can join

This trial is open to adults aged 18 and older. It includes men and women who have certain types of lymphoma or other specific blood conditions. Participants must have measurable disease and meet other health criteria. The trial team will confirm who is eligible to join.

What happens during the trial

Participants are placed into different groups for treatment. Some receive ascorbic acid with chemotherapy, while others receive a placebo (a harmless solution) with chemotherapy. Everyone will follow the same treatment schedule, which includes several cycles of chemotherapy and various tests throughout the study. Some groups are currently closed to new participants.

The trial team

The trial is sponsored by the Mayo Clinic and has collaboration from the National Cancer Institute. The lead investigator is Dr. Thomas E Witzig from the Mayo Clinic.

Important dates

The trial started on March 23, 2018, and is expected to finish by November 2, 2033. It is currently enrolling new participants.

Additional information

The trial ID is NCT03418038. This is a Phase 2 trial, meaning it is looking at how well the treatment works and its safety. The trial is regulated by the FDA and aims to include about 80 participants.

Similar trials

Other recruiting trials for the same condition, with the eligibility rules written in plain language.

Browse similar trials
Talk to a specialist

Find a top oncologist who can tell you whether a trial is a sensible option for you.

Find a doctor
Cancer hospitals

The cancer centers running studies like this one, and what each is known for.

Browse hospitals